Lixte Biotechnology Holdings, Inc. (LIXTW)
USD 0.02
(-38.92%)
USD 0.02
(-38.92%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 5.09 Million | 6.31 Million | 6.72 Million | 3.26 Million | 2.49 Million | 2.13 Million |
| Selling, General and Administrative Expenses | 4.19 Million | 4.96 Million | 4.98 Million | 2 Million | 1.66 Million | 2.09 Million |
| Research and Development Expenses | 898.1 Thousand | 1.34 Million | 1.73 Million | 1.22 Million | 820.9 Thousand | 40.7 Thousand |
| Other Expenses | - | - | - | 33.8 Thousand | - | - |
| Cost and Expenses | 5.09 Million | 6.31 Million | 6.72 Million | 3.26 Million | 2.49 Million | 2.13 Million |
| Operating Income | -5.09 Million | -6.31 Million | -6.72 Million | -3.26 Million | -2.49 Million | -2.13 Million |
| Interest Expense | - | 8875.00 | 7414.00 | 3674.00 | - | 4923.00 |
| Income Tax Expense | - | -7821.00 | 6788.00 | -1558.00 | -49.72 Thousand | -9846.00 |
| Earnings before Tax | -5.08 Million | -6.31 Million | -6.72 Million | -3.26 Million | -2.44 Million | -2.13 Million |
| Net Income | -5.08 Million | -6.3 Million | -6.73 Million | -3.26 Million | -2.39 Million | -2.13 Million |
| Earnings Per Share Basic | -2.66 | -39.85 | -5.00 | -2.89 | -2.14 | -2.18 |
| Earnings Per Share Diluted | -2.66 | -39.85 | -5.00 | -2.89 | -2.14 | -2.18 |
| Weighted Average Shares Outstanding | 1.91 Million | 158.2 Thousand | 1.34 Million | 1.12 Million | 1.11 Million | 979.93 Thousand |
| Weighted Average Shares Outstanding (Diluted) | 1.91 Million | 158.2 Thousand | 1.34 Million | 1.12 Million | 1.11 Million | 979.93 Thousand |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | 3207.00 | -1054.00 | -7951.00 | 1558.00 | -2.49 Million | 4923.00 |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 1 Million | 966.87 Thousand | 5.09 Million | 1.02 Million | 132.48 Thousand | 1.66 Million |
| Selling, General and Administrative Expenses | 798.44 Thousand | 847.81 Thousand | - | 876.83 Thousand | 534.01 Thousand | 862.57 Thousand |
| Research and Development Expenses | 210.7 Thousand | 119.06 Thousand | - | 149.07 Thousand | 132.48 Thousand | 427.45 Thousand |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 1 Million | 966.87 Thousand | 5.09 Million | 1.02 Million | 1.02 Million | 1.66 Million |
| Operating Income | -1 Million | -966.88 Thousand | -5.09 Million | -1.02 Million | -1.02 Million | -1.66 Million |
| Interest Expense | 4154.00 | 7186.00 | -16.23 Thousand | 10.14 Thousand | -279.00 | 1948.00 |
| Income Tax Expense | - | -966.87 Thousand | -5090.24 | -1026.91 | -1024.18 | -766.00 |
| Earnings before Tax | -1.01 Million | -971.32 Thousand | -5.08 Million | -1.03 Million | -1.01 Million | -1.66 Million |
| Net Income | -1.01 Million | -971.32 Thousand | -5.08 Million | -1.03 Million | -1.01 Million | -1.66 Million |
| Earnings Per Share Basic | -0.45 | -0.43 | - | -0.46 | -0.49 | -1.00 |
| Earnings Per Share Diluted | -0.45 | -0.43 | - | -0.46 | -0.49 | -1.00 |
| Weighted Average Shares Outstanding | 2.24 Million | 2.24 Million | 1.91 Million | 2.24 Million | 2.07 Million | 1.66 Million |
| Weighted Average Shares Outstanding (Diluted) | 2.24 Million | 2.24 Million | 1.91 Million | 2.24 Million | 2.07 Million | 1.66 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -1 Million | -966.88 Thousand | - | -1.02 Million | -1.02 Million | -1.66 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
SY
FRAS
DTCY3
DUROPLY
BLMS
SPS